Fidelity
Home > Boards > US OTC > Medical - Drugs > Cellceutix Corporation (CTIX)

Cellceutix has stated several times that there isn't

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
KarinCA Member Profile
Member Level 
Followed By 324
Posts 17,557
Boards Moderated 10
Alias Born 11/16/07
160x600 placeholder
Study Shows Cellceutix Antibiotic Active Against Drug-Resistant Superbug Klebsiella Pneumoniae "Marketwired" - 4/14/2014 6:30:00 AM
Cellceutix Comments on Positive FDA Advisory Vote for Dalbavancin and Tedizolid "Marketwired" - 4/1/2014 8:00:00 AM
Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI "Marketwired" - 3/31/2014 9:25:00 AM
Cellceutix Initiates Clinical Trial of Prurisol as New Treatment for Psoriasis "Marketwired" - 3/25/2014 6:00:00 AM
Cellceutix to Initiate Psoriasis Clinical Trial "Marketwired" - 3/21/2014 6:00:00 AM
Seventh Cohort Underway in Cellceutix Clinical Trial of Kevetrin for Solid Tumors "Marketwired" - 3/19/2014 8:40:37 AM
Cellceutix Reports 14 Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Patients Treated in Phase 2b Clinical Trial "Marketwired" - 3/10/2014 6:00:00 AM
Cellceutix Expands to Gram-Negative Bacterial Infections "Marketwired" - 3/5/2014 6:00:00 AM
Cellceutix Enrolls First Patients in Phase 2b ABSSSI Clinical Trial "Marketwired" - 2/26/2014 6:00:00 AM
Cellceutix Selects Dr. Reddy's Laboratories for Formulation of Brilacidin for Ophthalmic and Otitis Infections "Marketwired" - 2/24/2014 7:00:00 AM
Cellceutix Submits Investigational New Drug Application (IND) for Clinical Trial of New Anti-Psoriasis Drug, Enrollment Under... "Marketwired" - 2/18/2014 7:00:00 AM
Cellceutix Files With FDA for Phase 2b Clinical Trial of Novel Antibiotic Brilacidin; Enrollment of Patients Expected to Star... "Marketwired" - 2/3/2014 7:00:00 AM
Cellceutix Sees Increased Valuation Potential for Its Novel Antibiotic Brilacidin "Marketwired" - 1/21/2014 7:00:00 AM
Cellceutix Provides Updates on Clinical Trials and Developments of Its Anti-Cancer, Anti-Psoriasis, and Antibiotic Compounds "Marketwired" - 1/15/2014 8:00:00 AM
Cellceutix Corporation to Present at Biotech Showcase 2014 "Marketwired" - 1/13/2014 7:00:00 AM
Cellceutix Submits Application to Institutional Review Board to Commence Clinical Trials of Anti-Psoriasis Drug Prurisol "Marketwired" - 1/6/2014 8:00:00 AM
Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis With US FDA "Marketwired" - 12/20/2013 7:55:15 AM
Cellceutix Submits Application for IRB Review to Commence Phase 2b Clinical Trial of Novel Antibiotic Brilacidin "Marketwired" - 12/16/2013 7:00:00 AM
Cellceutix Updates on Current Status of Programs "Marketwired" - 12/9/2013 7:00:00 AM
Cellceutix Identifies Drug Candidates for Gram-Negative and Candida Fungal Infections "Marketwired" - 11/18/2013 7:00:00 AM
Cellceutix to Pursue Significant Conjuctivitis and Kerititis Ocular Markets With Novel Antibiotic Brilacidin "Marketwired" - 11/4/2013 7:00:00 AM
Cellceutix Enters Into New $20 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC "Marketwired" - 10/28/2013 7:00:00 AM
Cellceutix Structures for Significant Growth in Upcoming Year "Marketwired" - 10/21/2013 7:00:00 AM
Cellceutix Drug Brilacidin(TM) May Be the Key Antibiotic on the Horizon for Serious Skin Infections; Plans to Start Phase 2b ... "Marketwired" - 10/14/2013 7:00:00 AM
Cellceutix Antibiotic Brilacidin Chosen by Elsevier as "Top Project to Watch" in Infectious Disease "Marketwired" - 10/10/2013 7:00:00 AM
KarinCA Member Level  Sunday, 12/23/12 12:54:34 PM
Re: Gratefullife post# 15360
Post # of 58791 
Cellceutix has stated several times that there isn't competition to their drug kevetrin. Several companies have been working on it, but, none have achieved the same results. Kevetrin works on both the mutated and wild type p53. The competition seems to only work on the wild form. Kevetrin will end up working on many more cancers since it works on the mutated form.

Kevetrin is an HDAC-2 and HDAC-6 regulators. HDM2 is an inhibitor.

Kevetrin has several other subordinate activities, such as, regulating c-myc activity, inducing apoptosis, etc.. It has also been seen that Kevetrin has anti-angiogenic properties.

See my earlier post including info from company: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82597857

See progressive post of earlier PR dealing with this: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=82732988

Also, see search of FDA website for the other companies trials and you will notice HDM2 isn't listed yet.
http://www.clinicaltrial.gov/ct2/results?term=Ascenta+Therapeutics%2C+Inc&Search=Search



KarinCAtrades.com

GLTA... KarinCA ;)

"Be kinder than necessary, for everyone you meet is fighting some kind of battle."

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist